Is Auxly Cannabis a Buy?

Momentum continues to pick up for the marijuana industry. But not every marijuana stock is prospering.

Auxly Cannabis  (NASDAQOTH:CBWTF) lost more than half its value in 2018, making it one of the 10 worst-performing marijuana stocks of the year. So far in 2019, the stock is down close to 20% while the shares of many of its peers are soaring. But is Auxly now such a bargain that it’s a great pick for long-term investors to buy?

THE GOOD

Auxly’s share price hasn’t reflected the tremendous potential the company has. But that potential exists nonetheless.

Estimates vary about just how big the global marijuana market could be. However, projections of $100 billion or more within the next decade don’t appear to be unrealistic. Auxly itself estimates that the total market could be close to $50 billion by 2024. The company doesn’t have to be a big player in a market of that size to be enormously successful.

Auxly offers one key advantage to investors that most marijuana stocks don’t: diversification across the cannabis supply chain. The company’s revenue streaming partnerships, joint ventures, equity investments, and subsidiaries make Auxly a player in the upstream cultivation, midstream extraction and processing, and downstream distribution and sales segments of the cannabis industry.

THE BAD

Despite its impressive efforts in wheeling and dealing, Auxly has yet to make even a cent of profit. In the third quarter of 2018, the company posted a loss totaling nearly 4.6 million Canadian dollars, or around $3.5 million.

Auxly’s problem isn’t just that it’s spending a lot of money (which it is); the company simply isn’t making much revenue, either. In Q3, Auxly’s revenue totaled a measly CA$512,000 — roughly $385,000.

The primary issue for Auxly is that most of its upstream partners are still ramping up their production capacity. They can’t sell what they can’t produce.

Read the full article at The Motley Fool

Could Mushrooms Be The Next Drug To Be Decriminalised?

“Marijuana and magic mushrooms. One’s a plant, one’s a fungi, both are illegal – for now.

But psychedelic drug reform is already happening in the US. The city of Denver, which has already legalized recreational cannabis, is preparing to vote on whether to decriminalize magic mushrooms in May.

With New Zealand moving towards a referendum on our cannabis laws, News-hub spoke to Victoria University drug use expert Dr Fiona Hutton about whether or not we need to take a look at our laws on mushrooms.

Magic mushrooms (or shrooms) contain psilocybin, which is converted in the body to the psychedelic substance psilocin. They’re classified as Class A, meaning they come with the strongest penalties if you get caught with them.

Possession is a maximum of six months in prison – while the maximum penalty for supply is life in prison.

In medical trials, patients reported improvements in anxiety and depression. Other studies found psilocybin could help users kick their drug, alcohol, and nicotine addictions.

In the US, drug researchers, including Johns Hopkins University researcher Dr Matthew Johnson, said they were worried about the risk of bad trips and how people with psychotic disorders could be affected.

According to the 2017 annual Global Drug Survey, which relies on self-reported drug use, the rate of users who needed emergency medical care after using mushrooms was three times lower that of cannabis.

And research by UK drug expert Prof Nutt found that mushrooms were statistically the least dangerous out of 20 drugs, including alcohol, tobacco, cannabis and LSD.

Read the full article at Newshub

Denver Should Legalize Magic Mushrooms

“The decriminalization of magic (psilocybin) mushrooms is going to be on the ballot in Denver in May, and voters should definitely go for it.

On February 1, the Denver Elections Division certified a petition from decriminalization activists, noting that it had received enough signatures for voters to decide on the issue in the municipal election. The measure would decriminalize the use of psilocybin — or “magic” — mushrooms within city limits.

It’s important to note that the measure would not legalize the drug, but simply make stopping possession of it a low priority for police, prohibiting the city and county from using any of its resources to punish people ages 21 and older for possessing the drug. The drug would still, of course, be considered illegal on the federal level.

Although mushrooms are a drug that may carry a lot of stigma, voters would be right to pass this measure in May. In fact, speaking generally, I would argue that drug decriminalization is always the right choice. After all, we are supposed to be a country that was founded on the principles of freedom and individual liberty, and locking people up for what they choose to put in their own bodies certainly seems opposite to that philosophy.

Another study suggests that mushrooms are also helpful for the mental health of those who are suffering with life-threatening illnesses. In 2016, a Johns Hopkins study reported that cancer patients who had received psilocybin experienced an average 78 percent reduction in depression and an 83 percent reduction in anxiety.

Read the full article at National Review

How Will Denver Change if it Decriminalizes Magic Mushrooms?

“The Mile-High City might be about to get a bit higher. In May, the citizens of Denver, Colorado, will vote on whether or not to decriminalize magic mushrooms, the colloquial name given to a group of mushroom species that contain the psychoactive compound psilocybin.

In the US, psilocybin is classified as a Schedule I drug, taking a place alongside heroin and ecstasy, ostensibly as one of the most dangerous drugs around. However, this classification doesn’t seem to jibe with the scientific consensus on magic mushrooms.

Psilocybin is typically not abused and is not addictive (in fact, some research has shown it to reduce addiction to other drugs). Furthermore, it does indeed have some medical purposes. Research has shown that its impact on depression, anxiety, and other psychological conditions is profound.

But Denverites aren’t talking about legalizing magic mushrooms purely for their medicinal properties; rather, they will be voting on whether or not to decriminalize the drug. First, decriminalization does not mean legalization—buying and selling the drug will still be illegal, but using and possessing it will simply not be prosecuted. Since this means the infrastructure to support its medical use won’t exist, we can assume that more Denverites will be using the drug recreationally.

If decriminalization and eventual legalization go ahead in Denver, what will this mean? Well, in addition to hallucinations, a distortion of time, and a sense of connectedness to the universe, magic mushrooms also have some more interesting long-term effects. First, some studies show that psilocybin usage can make people experience greater personal meaning, spiritual significance, and life satisfaction even six months after their initial dose.

Continue Reading at Big Think

Inside the Push to Legalize Magic Mushrooms for Depression and PTSD

“IT WASN’T. The former corporate executive from Colorado retired in 2006 after an MRI revealed his spine was riddled with a dozen tumors called hemangiomas, which later spread to his brain. Todd was told he would die before the end of 2008.

Somehow, Todd has survived—he credits medical marijuana, which he now uses daily—but he is still considered terminal. “It could be tomorrow. It could be five years from now,” he says in a call.

However, the 54-year-old spent the past decade plagued by a host of mental health problems, including PTSD and treatment-resistant depression. He was suicidal and tormented by violent night terrors. Nothing, not even massive doses of Xanax or Valium, could temper his panic attacks or end-of-life anxiety.

That was about a year ago. Todd began taking homegrown psilocybin, the highly illegal alkaloid in so-called magic mushrooms. Known for prompting profound hallucinations, psilocybin was placed in the restrictive Schedule I category in 1970, meaning the US government recognizes no medical use for the drug and says that it carries a high risk of abuse.

Todd says there have been clear benefits from psilocybin with few side effects. He hasn’t had a single PTSD episode since he began taking it. His depression evaporated. The mushrooms even help ease the pain—agony that feels like being “shot in the back”—from the nerve-crushing tumors in his spine and skull.

Indeed, magic mushrooms are having a therapeutic moment. In North America, at least four organizations, each with unique strategies, are working to expand access to psilocybin for anyone with mental health issues, dying or not. These groups hope to undo decades of psilocybin prohibition by removing criminal penalties for possession or cultivation, or by providing access to psilocybin in a therapist’s offices, or both.

Read more at Wired

The Failing Battle Against Drug Production in Colombia

”Despite several strategies to eradicate domestic cocaine production, Colombia continues to struggle with the massive amount of drugs that are cultivated and manufactured within its borders. Government control measures include the arrest of major drug lords and the dismantling of their cartels, as well as the prosecution of corrupt politicians and police officers involved in the drug trade.

Colombia is a world leader in cocaine cultivation and a major heroin supplier to the world. Coca leaves, the key ingredient in cocaine production, are grown in Colombia’s Andes Mountains. This area has been the focus of crop eradication for decades.

From 2000 to 2005, the United States appropriated about $4.3 billion for the Andean Counter-Drug Initiative, according to a report from the Congressional Research Service. The funds were targeted to eradicate the coca and opium poppy plants used to produce the illicit drugs.

The International Agency for Research on Cancer, a World Health Organization affiliate, found in 2015 that the aerial pesticide spray glyphosate (also known as Roundup) exposed Colombian farmers and villagers to a possible carcinogenic. Consequently, the Colombian government banned its use after it had been on the market for nearly two decades.

The next strategy was to send government workers into remote mountainous areas where farmers cultivate cocaine and heroin ingredients and offer them crop substitution as a new solution. The goal was to entice farmers to replace their illicit crops with legitimate ones, such as fruits and vegetables.

The goal of the peace treaty was to end the epidemic of violence and formulate a definitive solution to Colombia’s drug problem. As part of the deal, Bogota promised to provide health and education services along with potable water in rebel lands. FARC members were also granted amnesty for their crimes.

However, the Insight Crime Foundation, which tracks organized criminal groups, estimates that as many as 2,800 FARC members rejected these peace efforts. They rearmed themselves, demonstrating the ineffectiveness of the treaty.

Read more at In Homeland Security

8 Things Everyone Gets Wrong About CBD

“The past year has seen a surge of interest in marijuana’s CBD, a non-intoxicating cannabis compound with significant therapeutic properties. Numerous commercial start-ups and internet retailers have jumped on the CBD bandwagon, touting CBD derived from industrial hemp as the next big thing, a miracle oil that can shrink tumors, quell seizures, and ease chronic pain — without making people feel “stoned.” But along with a growing awareness of cannabidiol as a potential health aid, there has been a proliferation of misconceptions about CBD.

CBD is Medical. THC is recreational

Project CBD receives many inquiries from around the world and oftentimes people say they are seeking “CBD, the medical part” of the plant, “not THC, the recreational part” that gets you high. Actually, THC, “The High Causer,” has awesome therapeutic properties. Scientists at the Scripps Research Center in San Diego reported that THC inhibits an enzyme implicated in the formation of beta-amyloid plaque, the hallmark of Alzheimer’s-related dementia.

THC Is The Bad Cannabinoid. CBD is the good cannabinoid

The drug warrior’s strategic retreat: Give ground on CBD while continuing to demonize THC. Diehard marijuana prohibitionists are exploiting the good news about CBD to further stigmatize high-THC cannabis, casting tetrahydrocannabinol as the bad cannabinoid, whereas CBD is framed as the good cannabinoid. Why? Because CBD doesn’t make you high as THC does.

CBD Is Most Effective Without THC

THC and CBD are the power couple of cannabis compounds — they work best together. Scientific studies have established that CBD and THC interact synergistically to enhance each other’s therapeutic effects. British researchers have shown that CBD potentiates THC’s anti-inflammatory properties in an animal model of colitis.

Continue Reading at The Growth Shop

Scientists Find Psilocybin Microdosing Can Boost Cognitive Creativity

Recent research on LSD indicates the drug has potential to treat mental disorders and improve our understanding of human consciousness. Meanwhile, studies in recent years have explored the effects of psilocybin—the psychoactive compound occurring naturally in magic mushrooms—on quitting smoking; lowering violent crime; treating depression, anxiety, and post-traumatic stress disorder; and triggering spiritual epiphanies.

Now, an Oct. 25 study in Pharmacology—the official journal of the European Behavioral Pharmacology Society—adds to this growing body of knowledge. It examines another potential benefit of psilocybin. Researchers from Leiden University in The Netherlands studied the cognitive effects of micro-dosing psilocybin truffles (technically not mushrooms, but instead the hardened vegetative part of a fungus). They found that tiny doses can stimulate brain function and boost creativity without harming reasoning abilities.

Microdoses contain about 10% of the psychoactive components of a standard dose of psilocybin. The idea is to get the benefits but not the downsides of the drug, minimal effects that can stimulate thinking but not lead to extremes, like hallucinations.

For this study, the researchers tested the effects of about .035 grams of a psychoactive truffle on 36 subjects. (They later did a chemical composition analysis of the truffles to make sure psilocybin was evenly distributed throughout the truffles.) They investigated three types of thinking by presenting the subjects with different three tasks—developed by psychologists to test cognition—which was performed both before and after ingesting the drug. The scientists studied subjects’ convergent thought, which involves identifying a single solution for a single problem; their fluid intelligence, or reasoning and problem-solving; and their divergent thinking, the ability to recognize many solutions.

Read more at Quartz

The Problems with the UK’s Legalization of Medical Cannabis

Since last Thursday, medical cannabis has been legal in the UK. This means specialist doctors are now able to prescribe cannabis products for conditions where there is a proven medical benefit, potentially helping thousands of people suffering from severe forms of epilepsy, multiple sclerosis (MS), chronic pain, and nausea as a result of chemotherapy, among other ailments.

This landmark change in the law occurred after several stories came to light of sick children suffering under prohibition, including Billy Caldwell. The severely epileptic 12-year-old hit headlines earlier this year when the Home Office confiscated the Canadian-bought cannabis oil that made his condition manageable. Nationwide horror at the situation prompted Home Secretary Sajid Javid to order a review of the law, after which it was decided that cannabis should be changed from a Schedule 1 drug (no medical value) to a Schedule 2 (can be prescribed).

An MS Society statement said: “It’s likely that nothing will change in the short-term for the one in ten people who get relief from pain and muscle spasms by using medical cannabis. We’re calling for the interim guidance of prescribing medical cannabis to be urgently reviewed so that access to the treatment isn’t so restricted.”

Despite the limited scope laid out in the guidelines, Health Secretary Matt Hancock seemed to imply that doctors are being given a certain level of flexibility. He said: “Doctors need to use their clinical judgment, and having guidance in place helps. Ultimately, the need to treat a person and the responsibility for that falls on the shoulders of a doctor—that’s what they do.” Indeed, there will be no direct policy from a government that limits the conditions for which medical cannabis can be prescribed.

Read the full article at Vice

Report Says: More Women Are Using Marijuana During Pregnancy

Between 2002 and 2016, the percentage of pregnant women who reported smoking cigarettes while expecting fell significantly: from 17.5% to about 10%, according to a research letter published Monday in JAMA Pediatrics. Alcohol use also fell modestly during this period, from nearly 10% to about 8.5%. But cannabis use among pregnant women — while still relatively rare — is on the rise, increasing from almost 3% of pregnant women to almost 5%.

Those figures were based on responses to the National Survey of Drug Use and Health. About 12,000 pregnant women ages 18 to 44 responded to the survey between 2002 and 2016; roughly 3,500 of these women were in their first trimester of pregnancy, a critical time for fetal development.

Meanwhile, the decline in smoking cigarettes while pregnant corresponds with an overall decrease in the number of Americans who smoke. The percentage of smokers in the U.S. hit a new low recently, dropping from 45.1 million cigarette users in 2005 to 36.5 million, or about 15% of the population, in 2015. The researchers did find, however, that decreases in smoking were less pronounced among specific subgroups of pregnant women, including black women, women ages 26 to 44 and those who did not finish high school.

There is far less research on the health effects of marijuana, but in general, the CDC and other public health organizations have warned expectant mothers not to use the drug while pregnant, due to potential developmental harms for infants. Similar warnings exist for smoking cigarettes while pregnant.

Time

Cannabis Extract Relieves Chronic Pain Minus The High

In the wake of cannabis legalization in Canada, a team of scientists has delivered encouraging news for chronic pain sufferers by pinpointing the effective dose of marijuana plant extract cannabidiol for safe pain relief without the typical “high” or euphoria that THC produces. The findings of their study have been published in the journal PAIN.

Cannabis indica and sativa are the two main cannabis strains that produce the pharmacological principles known as tetrahydrocannabinol (THC) and cannabidiol (CBD). The team demonstrated that CBD does not act on the CB1 cannabinoid receptors like THC, but through the mechanism that binds specific receptors involved in anxiety (serotonin 5-HT1A) and pain (vanilloid TRPV1).

“In animal models of neuropathic or chronic pain, we found that low doses of CBD administered for seven days alleviate both pain and anxiety, two symptoms often associated,” says the study’s first author Danilo De Gregorio, a postdoctoral fellow at McGill University.

Lead author Gabriella Gobbi sees this as a new advancement for the evidence-based application of cannabis in medicine with CBD likely offering a safe alternative to THC and opioids for chronic pain, such as back pain, sciatica, diabetic, cancer, or post-trauma pain.

“Our findings elucidate the mechanism of action of CBD and show that it can be used as medicine without the dangerous side effects of the THC,” says Gobbi, a professor of psychiatry.

Despite widespread public usage, little clinical studies exist on CBD, which became legal in Canada on October 17, 2018, following the passage of Canada’s Cannabis Act.

Futurity

California’s Race to the Top on Cannabis

In essence, San Francisco is resetting the clock on the War on Drugs, at least for cannabis. The city is expanding upon Proposition 64, the state law that went into effect this year that makes amnesty for weed-related crimes a condition for legalizing cannabis in California.

As incredibly progressive as that ordinance is, San Francisco is not alone in attempting to work racial equity into the new legalized cannabis landscape. Cities across California and other states are upping the racial equity quotient in various ways, in what looks like a race to the top for seeking true racially and economically inclusive outcomes. As city leaders scratch their heads over how to realize real racial equity in policymaking, the legalized weed experiment is acting as the test case and is already proving itself sticky enough that cities are almost competing to be the most weedfully woke.

It’s not just the historically uber-liberal Bay Area that’s embarking on this. Los Angeles also has a cannabis social equity program that prioritizes business permits for people with low incomes, who have lived in an area ravaged by the drug war, have criminal records (because of past weed prohibition), and who plan to hire at least half of their workforces from local residents. Both Oakland and L.A. are also prioritizing permits for people who don’t personally fall under this criteria but are willing to finance or lease space to applicants who do.

Despite the heavy regulation of the cannabis market at both the city and state level (and maybe the federal level if Senator Cory Booker has it his way), there has still been immense growth in revenue and profits in this field. According to the 2017 Cannabis Industry Annual Report, from New Frontier Data, “The legal cannabis market was worth an estimated $6.6 billion in 2016, and annual sales are projected to grow at a compound annual growth rate (CAGR) of 16% to reach more than $24 billion by 2025.” And that’s only based on the states where weed is currently legal.

Read the full article at CityLab

Psychedelics Stop Oppression? Magic Mushroom Compound Shown To Soften Authoritarian Views

A new experimental research program has provided the first evidence that psilocybin, the psychoactive compound found in hallucinogenic mushrooms, might decrease authoritarian views.

“Magic” mushrooms have become inextricably linked to the nature-loving, political counterculture that often seeks them out. But what if psilocybin was actually what led people to exhibit those traits, rather than the other way around?

Scientists from the Psychedelic Research Group at Imperial College London conducted a study using seven participants with treatment-resistant depression, which refers to chronic depression that doesn’t respond to therapy or medication, or most likely a combination of the two.

The psilocybin group experienced a significant reduction in authoritarian leanings, with noticeable changes holding up even at the seven- to 12-month mark. The control group exhibited no such change. “These results suggest that psilocybin therapy may persistently decrease authoritarian attitudes post-treatment with psilocybin,” the team wrote in a new paper describing their research, which was published in the scientific journal Psychopharmacology.

There are substantial caveats to this study, the first being its sample size—seven people is an unusually small number for this sort of thing. Another is that it’s possible the reduction in depression the participants reported is what caused any ideological changes.

Newsweek

Ayahuasca: The Hallucinogen That Blows Your Mind

The first thing you should know about drinking ayahuasca is that it’s going to make you puke your brains out. That’s usually the first thing that anyone who has ever taken it will tell you. But once you get past that, they say, you will experience a high so deep and emotionally enlightening that your outlook on the universe will change forever.

Ayahuasca comes from two words from the Quechua, a South American tribe based primarily in the Andes: “Aya,” meaning spirit, and “Huasca,” meaning vine or rope. The Quechua call it the “vine of the soul” or “creeping spirits of the dead.” When you drink ayahuasca tea, you see the kind of powerful hallucinations akin to what one would see on LSD. Those who have taken ayahuasca report experiencing out-of-body experiences, “spiritual flights,” and powerful hallucinations. In some cases, they swear they’ve even experienced telepathy.

While some researchers have suggested that ayahuasca could potentially be used to treat those struggling with PTSD or substance abuse, there’s not much evidence to support its therapeutic benefits. In fact, ayahuasca has also been shown to have adverse effects for those struggling with mental health issues, particularly if they’re undiagnosed, as it could potentially trigger psychosis. Following the death of 24-year-old New Zealand student Matthew Dawson-Clarke last year, ayahuasca retreats have also garnered their fair share of negative media attention.

Read more at Mens Health

Canandaigua Community Leaders Talk About Opioid Crisis

CANANDAIGUA — People have been asking Canandaigua Mayor Ellen Polimeni about the opioid crisis, how serious of a problem it is and what parts of the community are primarily affected.

Narcan is a brand name for naloxone, a medication that almost instantly reverses the effects of an opioid overdose, virtually saving people from the brink of death.

Lynn Seaward, director of community-based services at Finger Lakes Area Counseling & Recovery Agency (FLACRA), talked about various local programs available to help drug and alcohol addicts, including peer services where those recovering can relate to and help abusers find the best services for their individual situations.

FLACRA also recently acquired a mobile crisis van that allows staff and peer counselors to go directly to people in crisis or overdosing. Staff also work with law enforcement and emergency personnel in rescuing people and educating families on the problems that lead to addiction and where to find help.

Read the full article at Daily Messenger

Are Magic mMushrooms Next On The List of Legalized Drugs?

OREGON — Oregon could become home to the legal, recreational use of magic mushrooms. A campaign to legalize Psilocybin, informally known as magic mushrooms, is making its way to voters.

Psilocybin, after all, is an off-patent, organic agent which creates change through the psychedelic experience it provides, such that a single experience often changes a person’s disposition moving forward,” the group wrote in an open letter to voters. “And the psilocybin model, which includes preparation, psychedelic facilitation, and integration afterward, doesn’t just match the effectiveness of a typical ‘meds and therapy’ regimen. Where typical interventions fail, psilocybin therapy, with impressive frequency, breaks through.

Psilocybin is a naturally occurring hallucinogen found in certain species of mushrooms. There are an estimated 180 species of mushrooms that contain psilocybin. Users typically experience hallucinations when they eat the mushrooms.

Continue Reading at Patch

Use of CBD Oil Has Doubled in the UK in One Year

A trade organization in the United Kingdom that oversees the rapidly expanding cannabidiol (CBD) and hemp market, has published a study that shows the use of CBD oil in the U.K. has doubled in a single year.

The Cannabis Trades Association U.K.’s (CTAUK) figures reveal 250,000 people are now using CBD oil to treat their health conditions. CTAUK added that the number of users is up from 125,000 last year, with approximately 1,000 new users each month.

In October 2016, the U.K. government recognized the medicinal value of CBD, stating the cannabinoid has “restoring, correcting, or modifying” properties. This admission has allowed suppliers to sell CBD by obtaining a medicinal license, which is a lengthy and strict process. Many retailers have been able to circumvent the process by selling CBD products as food supplements.

Most recently, the public debate around medical cannabis in the U.K. has seen a lot of attention, with a bill to legalize going through its first parliamentary reading Oct. 10 unopposed. That same day, a protest incited by a member of parliament and cannabis activist Paul Flynn took place in front of the Parliament building in London.

More of this news at Marijuana.com

Magic Mushroom Compound Could Treat Depression

A compound commonly found in “magic mushrooms” may work some magic on patients struggling with depression.

A study out of Imperial College London recently touted the benefits of psilocybin, the psychoactive compound found naturally in the mushrooms.

Researchers of the paper published in Scientific Reports said the psychedelic compound can hit the “reset button” on brain circuits that contribute to depression.

Researching the psychedelic compound is nothing new.

Dr. George Greer, medical director at Heffter Research Institute in New Mexico, is part of an organization that studies psilocybin to treat cancer, addiction, and other ailments.

In the study out of Imperial College London, 19 patients took 2 doses of psilocybin, a week apart.

Each patient had two brain scans following each dose.

Then, researchers looked at their brains using two imaging methods.

Read the full article at Healthline

Maine Lawmakers To Debate Sale Of Marijuana

AUGUSTA (WGME) – Maine voters approved recreational marijuana nearly a year ago, but there is still no market set up in the state.

The marijuana debate has yet to happen in the house or senate, but what we do know is Governor LePage and House Republicans seem to be ready to delay the sale of recreational marijuana in Maine.

Portland Senator Mark Dion says the marijuana legalization implementation committee he serves on worked for eight months on a bill that allows for the safe, regulated, taxed and legal sale of marijuana in Maine, which Maine voters approved.

But House Republican Leader Ken Fredette says the bill passed out of committee is far from ready. That’s why he is presenting a governor’s bill to delay the regulated sale of marijuana in Maine.

“There needs to be rulemaking done as part of passing this bill,” Fredette said. “And that rulemaking, in my opinion, is not going to be done anywhere near Feb. 1, 2018.”

The Republican chair of the Marijuana Legalization Committee says there is no need for a delay.

Read more at WGME

Can Cannabis Oil Boost Tilapia Development?

A team of scientists from the American University of Beirut fed Nile tilapia fish pellets laced with cannabis oil to test whether the drug could make the fish reduce stress and grow faster.

These researchers noted that tilapia is farmed intensively, and in a bid to maximize the amount of product fish farmers can bring to market, some fish pens have become incredibly congested. Living in such close quarters can lead to all kinds of challenges for the fish, including reduced water quality, more incidences of disease, and increasing intraspecific interactions, which leads to stress.

As part of the trial, three diets were made to contain either soy oil, industrial hemp oil or cannabis oil and offered to tilapia for 8 weeks. At termination, survival, growth, feed conversion and blood parameters were assessed.

On the other hand, cannabis had no effect on blood cell counts, total plasma protein, hematocrit or lysozyme activity.

The results thus obtained suggest that cannabis does not improve the immune response of tilapia or body composition but does reduce growth rate by increasing metabolic rate.

Therefore, the Lebanese scientists found that the pot pellets did not quite have the mood-altering effect they had hoped for.

Continue Reading at Fish Info & Services Co.Ltd